Clinical impact of adjuvant chemotherapy in glioblastoma multiforme : a meta-analysis.
BACKGROUND
A meta-analysis of chemotherapy for glioblastoma multiforme (GBM) was performed. We sought to update prior analyses by focusing exclusively on GBM, including new trials of novel treatments, assessing effectiveness of individual treatment categories and presenting data in a clinically useful format.


METHODS
A search of MEDLINE and EMBASE was conducted for randomised controlled trials of chemotherapy in GBM.


RESULTS
Relative risks (RRs) for survival in 16 trials comparing chemotherapy with no chemotherapy were 1.18 (95% CI 1.08, 1.30) at 6 months, 1.53 (95% CI 1.26, 1.86) at 12 months and 2.12 (95% CI 1.60, 2.80) at 24 months. Nitrosourea compounds, local therapy (e.g. carmustine [1,3-bis [2-chloroethyl]-1-nitrosourea] wafers) and temozolomide were all more effective than no chemotherapy. Absolute increases in survival at 6, 12 and 24 months were 11%, 8% and 1%, respectively, for nitrosourea compounds; 8%, 24% and 5%, respectively, for local therapy; and 4%, 15% and 17%, respectively, for temozolomide. Efficacy of local therapy and temozolomide peaked at 12 and 18 months, respectively. After 2 years, nitrosourea compounds no longer provided clinically relevant benefit (number needed-to-treat [NNT] = 100; effect size [ES] = 0.17 SD), local therapy had diminishing returns (NNT = 20) that remained clinically relevant (ES = 0.71 SD) and temozolomide continued to show good efficacy (NNT = 5.9; ES = 0.74 SD). Survival was not significantly improved with multi-agent versus single-agent nitrosourea-based therapy in five trials: 6-month RR 0.91 (95% CI 0.71, 1.16); 24-month RR 1.33 (95% CI 0.72, 2.46).


CONCLUSIONS
Although nitrosourea compounds, local therapy and temozolomide are all effective in the treatment of GBM, local therapy and temozolomide may be associated with greater response, with clinically significant benefits extending to 24 months. The timing of peak benefits of local and temozolomide therapy suggests this combination may be more effective than single-agent chemotherapy and warrants further study.
Spiegel
Brennan M R
BM
VA Greater Los Angeles Healthcare System, Los Angeles, California 90073, USA. bspiegel@mednet.ucla.edu
Esrailian
Eric
E
Laine
Loren
L
Chamberlain
Marc C
MC
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D017594:Publication Bias; D016032:Randomized Controlled Trials as Topic / Q000592:standards; D016019:Survival Analysis
D000970:Antineoplastic Agents
Cancer. 2001 Jul 15;92(2):420-33
11466698
J Neurooncol. 2002 Oct;60(1):53-9
12416546
J Clin Oncol. 2001 Jan 15;19(2):509-18
11208845
Oncology. 1996 Jan-Feb;53(1):43-6
8570130
Int J Radiat Oncol Biol Phys. 1979 Sep;5(9):1589-92
231595
Semin Oncol. 2003 Dec;30(6 Suppl 19):19-22
14765380
Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9
9218294
BMJ. 1995 Feb 18;310(6977):452-4
7873954
Ann Intern Med. 1997 May 1;126(9):712-20
9139558
J Clin Oncol. 2005 Apr 1;23 (10 ):2372-7
15800329
Surg Neurol. 1987 Mar;27(3):259-63
3544286
Clin Neurol Neurosurg. 1985;87(3):167-71
2996816
Cancer Clin Trials. 1979 Spring;2(1):43-8
229983
Neuro Oncol. 2003 Apr;5(2):79-88
12672279
Cancer Res. 1998 Feb 15;58(4):672-84
9485020
Cancer. 2003 Oct 15;98(8):1745-8
14534892
Cancer Res. 2004 Oct 1;64(19):6892-9
15466178
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD002092
16437440
J Neurosurg. 1986 Jan;64(1):53-7
3455717
Br J Cancer. 2005 Apr 25;92(8):1372-81
15812554
Cancer. 1983 Sep 15;52(6):997-1007
6349785
Eur J Cancer. 1991;27(5):568-71
1828963
Tumori. 1993 Jun 30;79(3):198-201
8236504
Cancer. 1980 Mar 15;45(6):1289-99
6244079
Ann Surg Oncol. 2006 Mar;13(3):291-301
16450219
Control Clin Trials. 1996 Feb;17(1):1-12
8721797
Cochrane Database Syst Rev. 2002;(4):CD003913
12519620
Cancer. 1993 Apr 15;71(8):2585-97
8453582
Biometrics. 1977 Mar;33(1):159-74
843571
J Surg Oncol. 1985 Mar;28(3):214-6
2983151
J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):481-6
10480340
J Clin Oncol. 2006 Mar 10;24(8):1253-65
16525180
Acta Neuropathol. 2005 Jan;109(1):93-108
15685439
Semin Oncol. 2004 Oct;31(5):635-44
15497116
Neurology. 1994 Aug;44(8):1479-83
8058153
J Clin Oncol. 2003 Apr 15;21(8):1485-91
12697871
N Engl J Med. 2005 Mar 10;352(10 ):987-96
15758009
Semin Oncol. 2003 Dec;30(6 Suppl 19):15-8
14765379